EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSUPAG00010021243
Gene Symbol: DHCR24
3 Cross references
208 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 8

Ensembl ID : ENSUPAG00010016475
Gene Symbol: LOC113175843
2 Cross references
102 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSUPAG00010005462
Gene Symbol: HMGCR
1 Cross references
270 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSUPAG00010018093
Gene Symbol: PDPK1
3 Cross references
240 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSUPAG00010017025
Gene Symbol: LOC113192776
2 Cross references
201 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSUPAG00010016702
Gene Symbol: NT5E
1 Cross references
247 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSUPAG00010019721
Gene Symbol: HTR1A
1 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSUPAG00010015717
Gene Symbol: HTR1B
1 Cross references
245 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSUPAG00010017008
Gene Symbol: HTR1E
1 Cross references
155 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSUPAG00010021762
Gene Symbol: HTR1F
3 Cross references
145 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSUPAG00010004485
Gene Symbol: HTR2A
1 Cross references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSUPAG00010004952
Gene Symbol: HTR2B
1 Cross references
204 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).